

CLINICAL **ADVISORY**

March | 2023

PharMerica

Moderna MONOVALENT COVID-19 Vaccine to be Discontinued from HHS Distribution Program

Issue

The Department of Health and Human Services (HHS) will discontinue distribution of Moderna's MONOVALENT COVID-19 vaccine for adults (ages ≥ 12 years old) and pediatrics (ages 6-11 years old) from the current federal distribution program, effective March 13, 2023.

Key Points

- Ordering for these Moderna MONOVALENT COVID-19 vaccines from the federal supply will end on March 13, 2023.
- Moderna MONOVALENT COVID-19 vaccines for individuals 6 years of age and older are set to expire in early April 2023, with no further shelf-life extensions provided.
- Any adult or pediatric Moderna MONOVALENT products ordered in the next few weeks will be short-dated to this early April expiration.
- Patients starting their primary series with Moderna MONOVALENT vaccines may not be able to complete their primary series with this same brand product, in which case a different COVID-19 vaccine may be administered to complete the primary series at a minimum interval of 28 days from the last COVID-19 vaccine dose ([per CDC](#)).
- After March 13, individuals 6 years of age and older seeking MONOVALENT, primary series vaccines will need alternative vaccines from Pfizer (ages 6 years and older) or Novavax (ages 12 years and older).
- Supply of Johnson & Johnson's Janssen COVID-19 vaccine is depleted and is no longer available for ordering.
- Availability of the Moderna and Pfizer BIVALENT vaccines for all age groups remains unchanged.
- This information pertains to federally provided COVID-19 vaccines and does not comment on future distribution plans as products become commercially available at the end of the Public Health Emergency.

Action Steps

PharMerica Pharmacies

- Proactively share this advisory with clients to apprise them of the impending change to federally provided Moderna MONOVALENT COVID-19 vaccines.
- Continue to provide COVID-19 vaccines to serviced facilities per received orders and established process.
- Until March 13, 2023, upon receiving orders for adult or pediatric Moderna MONOVALENT COVID-19 vaccine, remind clients that residents receiving a first primary series dose may be unable to receive the same product for their subsequent dose(s).
- After March 13, 2023, upon receiving orders for adult or pediatric Moderna MONOVALENT COVID-19 vaccine, alert clients if product is unavailable and provide alternative age-appropriate vaccine options.



Facilities

- Engage in shared clinical decision-making with residents seeking MONOVALENT primary COVID-19 vaccines and place orders for available products as appropriate.